<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458975</url>
  </required_header>
  <id_info>
    <org_study_id>PRTK15-TL/SONCHIMIO</org_study_id>
    <nct_id>NCT03458975</nct_id>
  </id_info>
  <brief_title>Targeted Delivery of Chemotherapy With Ultrasound and Microbublles</brief_title>
  <acronym>SONCHIMIO</acronym>
  <official_title>Targeted Delivery of Chemotherapy With Ultrasound and Microbubbles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US&#xD;
      waves engender a modulation of the permeability of biological barriers amplifying hence the&#xD;
      extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In&#xD;
      such a way, the bioavailability of the therapeutic agent is augmented only in the area where&#xD;
      US waves are focused. The objective now is to translate this therapeutic approach to the&#xD;
      clinic by performing a feasibility study with the development of a therapy regime optimized&#xD;
      for hepatic metastases of colorectal cancer.&#xD;
&#xD;
      In order to demonstrate the clinical feasibility of the therapeutic approach based on&#xD;
      ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal&#xD;
      cancer treated with monoclonal antibodies in combination with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the increasing number of active molecules and the availability of news targeted&#xD;
      therapies for cancer, therapeutic achievements remain modest for a number of tumor types. One&#xD;
      of the major obstacles is inherent to the absence of specific delivery in the tumor tissue.&#xD;
&#xD;
      We have demonstrated recently that the oscillations of ultrasound (US) contrast agent&#xD;
      microbubbles under their activation by US waves engender a modulation of the permeability of&#xD;
      biological barriers amplifying hence the extravasation of drugs and/or fluorescent markers&#xD;
      through a process known as sonoporation. In such a way, the bioavailability of the&#xD;
      therapeutic agent is augmented only in the area where US waves are focused. The objective now&#xD;
      is to translate this therapeutic approach to the clinic by performing a feasibility study&#xD;
      with the development of a therapy regime optimized for hepatic metastases of colorectal&#xD;
      cancer.&#xD;
&#xD;
      In order to demonstrate the clinical feasibility of the therapeutic approach based on&#xD;
      ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal&#xD;
      cancer treated with monoclonal antibodies in combination with chemotherapy.&#xD;
&#xD;
      The work aims into evaluating the therapeutic efficacy of the proposed approach on a number&#xD;
      of selected patients. We will follow the usual treatment schemes and we will apply imaging&#xD;
      protocols to visualize tumor progression.&#xD;
&#xD;
      This technique of optimization of the intratumoral availability of anticancer drugs and based&#xD;
      on sonoporation will improve the efficacy and safety of systemic chemotherapy by providing&#xD;
      increased tumor uptake relative to normal tissue. This technique provides an ideal and easy&#xD;
      strategy to optimize intratumoral drug delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response for liver metastases</measure>
    <time_frame>2 months</time_frame>
    <description>Objective response for liver metastases with spiral CT scan and defined as decrease of at least 30% in the longer diameter of each selected liver metastases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Day 3, Day 17, Day 32, Day 47</time_frame>
    <description>Safety based on National Cancer Institute (NCI), Common Terminology Criteria for Adverse events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Day 3, Day 17, Day 32, Day 47</time_frame>
    <description>Tolerance based on National Cancer Institute (NCI), Common Terminology Criteria for Adverse events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum percent reduction in tumor density on CT scan</measure>
    <time_frame>2 months</time_frame>
    <description>Maximum percent reduction in tumor density (Hounsfield units) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum percent reduction in tumor density on MRI</measure>
    <time_frame>2 months</time_frame>
    <description>Maximum percent reduction in tumor density from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor vascularity by Perfusion CT scan</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of tumor vascularity with Perfusion CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor vascularity by MRI</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of tumor vascularity with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor vascularity by Dynamic Contrast-Enhanced US (DCE-US)</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of tumor vascularity with Dynamic Contrast-Enhanced US (DCE-US)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of antibody anti-VEGF or anti-EGFR</measure>
    <time_frame>Day1, Day 3, Day 15, Day 17, Day 32, Day 45</time_frame>
    <description>Measures of serum concentration of antibody anti-VEGF or anti-EGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of antibody anti-VEGF or anti-EGFR by ELISA test</measure>
    <time_frame>Day1, Day 3, Day 15, Day 17, Day 32, Day 45</time_frame>
    <description>Pharmacokinetic of antibody anti-VEGF or anti-EGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of cytokines</measure>
    <time_frame>Day1, Day 3, Day 15, Day 17, Day 32, Day 45</time_frame>
    <description>Dosage of cytokines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Hepatic Metastases</condition>
  <arm_group>
    <arm_group_label>Selected liver metastases of the patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not-selected liver metastases of the patient</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Magnetic Resonance Imaging</description>
    <arm_group_label>Not-selected liver metastases of the patient</arm_group_label>
    <arm_group_label>Selected liver metastases of the patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Perfusion CT scan</intervention_name>
    <description>Perfusion Computerized tomography scan</description>
    <arm_group_label>Not-selected liver metastases of the patient</arm_group_label>
    <arm_group_label>Selected liver metastases of the patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast enhanced ultrasound</intervention_name>
    <description>Contrast enhanced ultrasound</description>
    <arm_group_label>Not-selected liver metastases of the patient</arm_group_label>
    <arm_group_label>Selected liver metastases of the patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sonoporation</intervention_name>
    <description>Gaseous microbubbles (Sonovue) combinated with Ultrasounds</description>
    <arm_group_label>Selected liver metastases of the patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with liver metastases from colorectal cancer; patient with minimum two liver&#xD;
             metastases which satisfy all the following criteria: diameter between 10 and 35 mm;&#xD;
             arterially enhancing liver metastases detected with contrast enhanced ultrasound&#xD;
             (CEUS); measurable liver metastases with CT-scan (Acceptability of a patient with more&#xD;
             than 4 metastases or a patient with an odd number of metastases ≥ 2).&#xD;
&#xD;
          -  age ≥ 18 years;&#xD;
&#xD;
          -  ECOG/OMS 0-1;&#xD;
&#xD;
          -  life expectancy of at least 12 weeks;&#xD;
&#xD;
          -  adequate bone marrow, liver and kidney function;&#xD;
&#xD;
          -  written informed consent obtained from subject;&#xD;
&#xD;
          -  subjects covered by or having the rights to social security;&#xD;
&#xD;
          -  bi-weekly chemotherapy regimen&#xD;
&#xD;
          -  neo-adjuvant standard chemotherapy or palliative standard chemotherapy (first or&#xD;
             second metastatic line) following the recommendations in force (national thesaurus of&#xD;
             digestive oncology - colorectal cancer chapter: Phelip JM, Benhaim L, Bouché O,&#xD;
             Christou N, Desolneux G, Dupré A, Léonard D, Michel P, Penna C, Rousseaux B, Tougeron&#xD;
             D, Tournigand C. &quot;Cancer colorectal métastatique&quot;. Thésaurus National de Cancérologie&#xD;
             Digestive, Janvier 2019, http://www.tncd.org).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous local treatment of selected liver metastases (radiofrequency,&#xD;
             radioembolization, …);&#xD;
&#xD;
          -  Indication for local ablative therapy of selected liver metastasis (radiofrequency&#xD;
             ablation or other validated hepatic-directed modality of treatment);&#xD;
&#xD;
          -  Previous malignancy other than colorectal adenocarcinoma within 3 years prior to the&#xD;
             inclusion with the exception for curatively treated basal cell carcinoma of the skin&#xD;
             and/or curatively resected in situ cervical or breast cancer;&#xD;
&#xD;
          -  Known contraindication to the injection of Sonovue®, of Gadolinium, of iodated&#xD;
             contrast agent;&#xD;
&#xD;
          -  contraindication to MRI or perfusion CT scan;&#xD;
&#xD;
          -  Patient under legal protection;&#xD;
&#xD;
          -  Pregnant or lactating woman, or woman with ability to procreate and without&#xD;
             contraception;&#xD;
&#xD;
          -  Inclusion in another therapeutic trial&#xD;
&#xD;
          -  Uracilemia greater than or equal to 150ng/mL (suggestive of a complete DPD&#xD;
             deficiency).&#xD;
&#xD;
          -  Presence of any material with potential interaction with ultrasound beam (metal, etc.)&#xD;
             or healing tissue, and which cannot be bypassed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayache Bouakaz, MD</last_name>
    <phone>+332 47 36 61 42</phone>
    <email>ayache.bouakaz@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Roussel</last_name>
    <phone>+33247479789</phone>
    <email>roussel@med.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hépatogastro-entérologie CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LECOMTE Thierry, Pr</last_name>
      <phone>+33 2 47 47 59 00</phone>
      <email>thierry.lecomte@univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>ROUSSEL Catherine, Mme</last_name>
      <phone>+33 2 47 47 97 89</phone>
      <email>roussel@med.univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>LECOMTE Thierry, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbubbles</keyword>
  <keyword>sonoporation</keyword>
  <keyword>hepatic metastases of colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

